Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1615-1622

  De Fronzo, R A ^a   Burant, C F ^b   Fleck, P ^c   Wilson, C ^c   Mekki, Q ^c   Pratley, R E ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; PROINSULIN;

ACUTE CHOLECYSTITIS; ADULT; AGED; ARTICLE; BODY WEIGHT; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRACTURE; GASTRITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DEATH; HEPATITIS; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SPONTANEOUS ABORTION; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; THIAZOLIDINEDIONES; URACIL;

EID: 84860711211     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2243     Document Type: Article

References (22)

1. Saydah SH, Fradkin J, Cowie CC 2004 Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B 2008 Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 31:173-175
3. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, De-Fronzo RA 2006 Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55:1430-1435
4. Nathan DM, Davidson MB, De Fronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B 2007 Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753-759
5. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, De-Fronzo RA 2007 Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 292:E871-E873
6. De Fronzo RA, Fleck PR, Wilson CA, Mekki Q 2008 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31:2315-2317
7. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, De Fronzo RA 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255
8. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE 2008 Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 93:103-109
9. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB 2006 Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704
10. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105
11. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP 2002 Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803
12. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M, Buchanan TA 2006 Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55:517-522
13. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556-1568
14. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S 2007 Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 9:166-174
15. Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S 2007 Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9:175-185
16. Riedel AA, Heien H, Wogen J, Plauschinat CA 2007 Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27:1102-1110
17. Deacon CF 2008 Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 9:402-413
18. Pratley RE 2009 Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 10:503-512
19. Bauer P 1991 Multiple testing in clinical trials. Stat Med 10:871-889; discussion 889-890
20. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q 2008 Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes (Abstract). Diabetes 57(Suppl 1):A143
21. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB 2006 Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 29:504-509
22. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE 2008 Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 10:1114-1124